Alirocumab

Drug / Medication

A PCSK9 inhibitor (monoclonal antibody) that lowers LDL by 50-60% and Lp(a) by 25%, with positive cardiovascular outcome data from the ODYSSEY trial. Often chosen based on insurance approval and ease of use (SureClick device).

Mentioned in 1 video

Videos Mentioning Alirocumab

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A PCSK9 inhibitor (monoclonal antibody) that lowers LDL by 50-60% and Lp(a) by 25%, with positive cardiovascular outcome data from the ODYSSEY trial. Often chosen based on insurance approval and ease of use (SureClick device).